Halozyme Therapeutics downgraded by Wells Fargo with a new price target

10/7/24 8:32:56 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HALO

Date	Price Target	Rating	Analyst
5/14/2025	$62.00	Overweight → Equal-Weight	Morgan Stanley
5/13/2025	$47.00	Market Perform → Underperform	Leerink Partners
10/7/2024	$58.00 → $62.00	Overweight → Equal Weight	Wells Fargo
9/19/2024	$52.00 → $57.00	Overweight → Neutral	JP Morgan
6/7/2024	$48.00 → $51.00	Overweight → Neutral	Piper Sandler
2/29/2024	$54.00	Outperform	TD Cowen
7/24/2023	$61.00	Buy	H.C. Wainwright
7/24/2023	$43.00 → $45.00	Buy → Neutral	Goldman